ORCHID PHARMA
|
|
BOM : 524372     NSE : ORCHPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Jun 07,2023 |
Price(EOD): βΉ 414.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 1,689.12 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ORCHID PHARMA | -1% | 4.2% | 38.1% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 5.9% | 17.9% |
DIVIS LABORATORIES | 0.5% | 4.8% | 0.3% |
CIPLA | -0.4% | 2.3% | -1.5% |
DR REDDYS LABORATORIES | 2.6% | -5.3% | 7% |
TORRENT PHARMACEUTICALS | 1.5% | 9.3% | 27.1% |
ABBOTT INDIA | 1.3% | -0.2% | 18.8% |
ZYDUS LIFESCIENCES | 0.3% | -1.9% | 41.3% |
ALKEM LABORATORIES | 0.8% | -5.8% | 9.5% |
FUNDAMENTAL ANALYSIS OF ORCHID PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ORCHID PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
30.59
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 55.25 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] 2.61
P/B Calculated based on Book Value of Rs 647.38 Cr
[Latest Year - Mar2022 - Consolidated Results ] 2.54
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 665.90 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-58% -42% 620% |
SHARE PRICE MOMENTUM OF ORCHID PHARMA
ORCHID PHARMA vs SENSEX
DEBT OF ORCHID PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.4 0.66 0.71 0.59 |
0.41 0.69 0.74 0.61 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ORCHID PHARMA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ORCHID PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
31.39% 190.58% 879.95% 879.95% |
17.83% 54.03% 1948.88% 1948.88% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
ORCHID PHARMA related INDICES
You may also like the below Video Courses
FAQ about ORCHID PHARMA
Is ORCHID PHARMA good for long term investment?
As on Jun 07,2023, the Fundamentals of ORCHID PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of ORCHID PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ORCHID PHARMA UnderValued or OverValued?
As on Jun 07,2023, ORCHID PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ORCHID PHARMA ?
As on Jun 07,2023, the Intrinsic Value of ORCHID PHARMA is Rs. 708.58 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 992.60
Fair Value [Median EV / Sales Model] : Rs. 708.58
Fair Value [Median Price / Sales Model] : Rs. 57.48
Estimated Median Fair Value of ORCHID PHARMA : Rs. 708.58
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is ORCHID PHARMA trading at a Premium or Discount?
As on Jun 07,2023, ORCHID PHARMA is trading at a Discount of -42% based on the estimates of Median Intrinsic Value!